Focus of the future: further treatment options and improved care for patients with hormone-positive breast cancer
Abstract
Oncotype DX is an established method for molecular testing of hormone-dependent breast tumors. The test is applied in the postoperative period in women with an unclear indication of adjuvant chemotherapy (CT).
However, cases of primary diagnosis are also subject to the decision-making process on the choice of treatment strategy, in which the treatment options are as follows: 1. primary surgery, 2. neoadjuvant CT, 3. neoadjuvant hormone therapy (ET). In unclear cases, molecular testing may be indicated, similar to the postoperative period.
Oncotype DX may also be important where surgery needs to be delayed, which is a current topic at the time of a coronavirus pandemic (COVID - 19). The article deals with the data associated with the primary molecular examination using the Oncotype DX test from a biopsy sample and its possible indications.